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Abstract: Insomnia is common among elderly people and nearly 30 to 40% of the adult population also suffer from 
insomnia. Pharmacological treatment of insomnia include the use of benzodiazepine and non-benzodiazepine drugs like 
zolpidem, zaleplon,Zopiclone. Although these drugs improve sleep ,their usage is also associated with number of adverse 
effects, Melatonin ,the hormone secreted by the pineal gland of all animals and human beings has been used for treatment 
of insomnias,since the timing of its secretion in humans as well as in most of the animals coincides with the increase of 
nocturnal sleep propensity.Because of its short half life,melatonin slow release preparations were introduced for treatment 
of insomnia. Recently ramelteon ,a selective MT1,MT2 receptor agonist with greater efficacy of action in treating 
insomnia has been used clinically and has been found effective in improving sleep quality ,sleep efficacy and also in 
reducing the sleep onset time when compared to melatonin or slow melatonin preparations.The mechanism of action of 
ramelteon in improving sleep is discussed in the paper. Another melatonergic drug agomelatine besides acting on 
MT1/MT2 receptors also displays 5-HT2c antagonism and this drug has been found effective as a novel antidepressant for 
treating major depressive disorders.Agomelatine besides causing remission of depressive symptoms also improves sleep 
quality and efficiency. Other antidepressants depressants that are in clinical use today do not improve sleep. There are 
other melatonergic drugs like tasimelteon ,6-chloromelatonin.But ramelteon and agomelatine deserve special attention for 
treatment of insomnia and sleep disturbances associated with depressive disorders and have promising role for treatment 
of sleep disorders. 
Keywords: Ramelteon, sleep, agomelatine, depression, insomnia, melatonin. 
INTRODUCTION 
 Melatonin (N-acetyl-5-methoxytryptamine; MT), first 
identified by Lerner et al. [1], is the major neurohormone 
secreted from the pineal gland mainly during dark hours of 
night and is released in higher concentrations into the 
cerebrospinal fluid [2]. The circadian pattern of pineal 
melatonin secretion is regulated by the suprachiasmatic 
nucleus (SCN) of the hypothalamus. A major portion of the 
SCN is projected to the supraventricular zone of the 
hypothalamus from where fibres proceed to terminate in the 
brain areas involved in sleep-wake regulation [3]. Sleep 
regulation involves interaction of two separate mechanisms, 
namely an endogenous biological-clock that drives the  
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circadian-rhythm of sleep-wake cycle (process-C) and a 
homeostatic process (process-S) that influences sleep-
propensity, that is determined by the duration of previous 
sleep episodes [4]. These two processes interact continuously 
and determine the consolidated bout of sleep at night and 
consolidated bout of wakefulness during daytime. Melatonin 
has been suggested to be involved in sleep regulation, since 
its nocturnal rise leads to “opening of the sleep gate” and 
augmentation of sleep propensity [5]. 
 Several studies have shown the importance of melatonin 
both for the initiation and maintenance of sleep [6]. In all 
diurnal animals and human beings, the onset of melatonin 
secretion coincides with the timing of increase in nocturnal 
sleep propensity [5]. As melatonin exhibits both hypnotic 
and chronobiotic properties, it has been used for the 
treatment of age-related insomnia as well as other primary 
and secondary insomnia states [7, 8]. 
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 Melatonin has also been used successfully for treatment 
of sleep problems related to perturbations of the circadian 
time keeping system like those caused by jet-lag, shift-work 
disorder or delayed sleep phase syndrome, and in children 
with chronic sleep-onset insomnia [7, 9-11]. The high 
density of MT1 and MT2 melatonin receptor subtypes in the 
hypothalamic SCN [12, 13] suggests that melatonin affects 
sleep and the sleep-wakefulness cycle by acting on these 
receptors. 
 The efficacy of melatonin in promoting and maintaining 
sleep has been demonstrated in a number of clinical studies 
undertaken both in children with chronic onset insomnia as 
well in adult and elderly patients with chronic insomnia; 
however, because of its short half life, its sustained effect in 
improving sleep quality could not be found uniformly in all 
clinical studies undertaken so far. 
 Hence prolonged release preparations of melatonin and 
melatonin agonists with a longer duration of action on sleep 
regulatory mechanisms have been developed. These include 
circadin, beta methyl 6-chlormelatonin, tasimelteon, 
ramelteon, agomelatine [14]. 
INSOMNIA 
 Insomnia is a sleep disorder characterized by poor quality 
of sleep with symptoms like difficulty in falling asleep, 
frequent awakenings during night time, early morning 
awakenings, etc. Such symptoms resultin fatigue, decreased 
memory, and impaired performance, all of which havea 
negative impact on health and quality of life. 
 Insomnia is most common among elderly people and is a 
major cause of physical and mental health impairment [15, 
16]. Nearly 30 to 40% of the adult population suffers from 
mild to severe insomnia [17]. The sequelae of insomnia 
include fatigue, reduced alertness, irritability and impaired 
concentration; all these symptoms have major negative 
impact on the quality of life [18-20]. In addition, due to its 
broad psychological and physiological impacts, insomnia has 
social consequences such as increased risk of accidents and 
reduced productivity [21]. Treatment of insomnia includes 
life style modifications like relaxation and cognitive 
therapies, behavioral techniques like sleep hygiene [22] and 
pharmacologic interventions that employ sedative-hypnotics 
of both benzodiazepine and non-benzodiazepe drugs. 
 The non-benzodiazepine drugs like zolpidem, zaleplon, 
zopiclone that are used, although effective in reducing sleep 
latency, exhibit only moderate efficacy in increasing sleep 
efficiency [23]. An ideal hypnotic drug is expected to 
decrease sleep latency as well to increase sleep efficiency 
and total sleep time. 
MELATONIN AND SLEEP 
 The role of melatonin in the control of sleep has been 
investigated in both diurnal and nocturnal species. Local 
injection of pharmacological amounts of melatonin (1 to 50 
?g) in the medial preoptic area of the rat hypothalamus 
during daytime increased total sleep time (TST) in a dose-
dependent manner mainly by increasing non-rapid eye 
movement (NREM) sleep [24]. Melatonin has been shown to 
induce sleep by altering the functions of the GABAA-
benzodiazepine receptor complex [25, 26]. In diurnal 
species, suppression of electrical activity in the SCN is 
suggested as the possible mechanism by which melatonin 
regulates sleep [27]. This effect is absent in MT1 knockout 
mice showing thereby the importance MT1 receptors in 
melatonin’s acute inhibitory effects on SCN electrical 
activity [28]. The MT1 and MT2 melatonin receptor subtypes 
are complementary in their actions and to some extent 
mutually substitute for each other [13]. The suppression of 
neuronal activity by melatonin is one of the possible 
mechanisms by which this hormone contributes to the 
regulation of sleep [29]. 
 As melatonin deficiency is suggested as a cause rather 
than a marker for insomnia in the elderly, melatonin 
replacement therapy has been advocated for treating 
insomnia in old age. Because melatonin is a natural 
(endogenous) hypnotic, it is suitable for long term use in 
elderly people due to its low toxicity and limited side effect 
profile. Indeed melatonin replacement therapy has been 
found beneficial in treating elderly insomniacs by 
significantly improving TST and sleep quality, and by 
reducing sleep onset latency (SOL) [8, 30-36]. 
 Reduced endogenous melatonin production seems to be a 
prerequisite for effective exogenous melatonin treatment of 
sleep disorders in the elderly [8]. A meta-analysis on the 
effects of melatonin in sleep disturbances at all age groups 
(including young adults with presumably normal melatonin 
levels) failed to document significant and clinically 
meaningful effects of exogenous melatonin on sleep quality, 
efficiency and latency [37]. However another meta-analysis 
involving 17 controlled studies has shown that melatonin 
was effective in increasing sleep efficiency (SE) and 
reducing SOL in elderly subjects [38]. 
 The relationship between sleep disturbances and low 
nocturnal melatonin production was investigated in a large 
population of insomniacs aged 55 years or more [8]. Elderly 
insomniacs with sleep problems excreted 9.0 ± 8.3 ?g of 6-
sulfatoxymelatonin (urinary melatonin metabolite) per night, 
whereas age matched healthy controls excreted 18.1 ± 12.7 
?g of 6-sulfatoxymelatonin per night, and younger subjects 
excreted 24.2 ± 11.9 ?g of 6-sulfatoxymelatonin per night. It 
was also observed that half of the elderly insomniacs 
excreted less than 8.0 ?g of 6-sulfatoxymelatonin per night. 
Within this latter subpopulation of 372 subjects, 112 had 
urinary 6-sulfatoxymelatonin values lower than 3.5 ?g per 
night [8]. 
 Studies carried out using 0.3-1 mg doses of melatonin, 
that produces physiological melatonin levels in the 
circulation, have shown that melatonin reduced SL and 
increased SE when administered to healthy human subjects 
during the evening [30, 33, 34]. Brain imaging studies in 
awake subjects have revealed that melatonin modulates the 
brain electrical activity pattern to one resembling that of 
actual sleep [39]. Use of melatonin for treatment of children 
with sleep problems also have been reported in a number of 
clinical studies. In a randomized double- blind placebo 
controlled trial conducted by the Dutch Sleep Center 
involving 62 children of 6-12 years suffering for more than 
one year from chronic idiopathic sleep onset insomnia, 
administration of melatonin (5 mg/day) for 4 weeks 
advanced sleep onset time significantly (by 57 minutes) and 
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decreased sleep latency [40]. Similarly, use of melatonin (5 
mg/day) in 105 medication free children aged 6-12 years 
diagnosed with ADHD (Attention Deficit Hyperactivity 
Disorder) significantly improved total sleep time [41]. The 
noteworthy feature emerging from these studies is that 
melatonin treatment in children can be sustained over a long 
period of time without any substantial deviation in puberty 
development, mental health scores, or sleep quality of the 
general Dutch population [42]. 
 The general efficacy of melatonin as a sleep promoting 
substance has been subject of debate [43]. A possible 
explanation for this is that administered melatonin doses are too 
low as suggested by the relative potencies of the recently 
developed melatonin analogues. Given that the reported lack of 
efficacy of melatonin could be related to the extremely short-
half life of the fast release melatonin preparations, the 
development of slow release formulations has occurred [44]. 
Circadin
®
, a 2 mg controlled-release preparation of melatonin, 
developed by Neurim (Tel Aviv, Israel) was approved by the 
European Medicines Agency (EMEA) as a monotherapy for 
primary insomnia in elderly subjects. Circadin
®
 was shown to 
improve the quality of sleep and morning alertness, to reduce 
SO, L and to improve the quality of life in middle-aged and 
elderly insomniacs [45-47]. 
Ramelteon 
 Ramelteon (Rozerem
®
, Takeda Pharmaceuticals, Japan) 
is a melatonergic hypnotic analogue that has been 
demonstrated in clinical trials to be effective and safe. It is a 
tricyclic synthetic analogue of melatonin with the chemical 
name (S)-N-[2-(1, 6, 7, 8-tetrahydro-2H-indeno[5, 4-b]furan-
8-yl)-ethyl]propionamide (Fig. 1). In 2005, Ramelteon was 
approved by the Food and Drug Administration (FDA) for 
treatment of insomnia. It is a selective agonist for MT1/MT2 
receptors without significant affinity for other receptor 
systems [48, 49]. In vitro binding studies have shown that 
ramelteon affinity for MT1 and MT2 receptors is 3-16 times 
higher than that of melatonin. The selectivity of ramelteon 
for MT1 has been found to be greater than that of MT2 
receptors. The selectivity of MT1 receptors by ramelteon 
suggests that it targets sleep onset more specifically than 
melatonin itself [50]. 
Melatonin Receptors in the SCN 
 An understanding of the existence of melatonin receptors 
in the SCN of the hypothalamus and their mechanism of 
action is essential for elucidating the actions of exogenous 
melatonin in sleep regulation. It was reported that 
administration of exogenous melatonin (30-300 pM or 7-70 
pg/mL) decreased the number of MT2 receptors in the SCN 
[51]. The decrease in MT2 melatonin receptor numbers 
induced by melatonin was found to be reversible with full 
recovery after 8 hr. However no such desensitization of MT1 
receptors has been reported by the same authors [52]. 
Desensitization of receptors by agonists is a normal process 
in G-protein coupled receptors and is a point to be 
considered while using melatonin for long term in supra 
physiological concentrations. However there is no clinical 
evidence for desensitization of melatonin receptors upon use 
with supraphysiological concentrations of melatonin. This 
has been demonstrated in experimental studies where use of 
melatonin receptor agonist S20098 for 14 days did not alter 
the sensitivity of photically responsive SCN cells to 
melatonin in the SCN neither in vivo (intraperitoneal or 
iontophoretic application of melatonin) nor in the SCN slices 
in vitro [53]. Expression of MT1 melatonin receptors has 
been found in the human SCN [54]. 
Pharmacokinetics of Ramelteon 
 Ramelteon is usually administered by the oral route and 
is absorbed rapidly from the gastrointestinal tract (84%) 
[55]. The half-life of circulating ramelteon is in the range of 
1 to 2 hr which is much longer than that of melatonin. The 
influence of age and gender on the pharmacokinetics and the 
pharmacodynamics of ramelteon were evaluated in healthy 
volunteers (young: 18-34 yr, elderly: 63-79 yr) after 
administration of a single dose of ramelteon. The clearance 
of ramelteon was significantly reduced in elderly compared 
to young individuals. No significant gender effect was 
observed [55]. 
 Ramelteon is metabolized mainly in the liver via 
oxidation of hydroxyl and carbonyl groups, and then 
conjugated with glucuronide [56]. Cytochrome P4501A2 is 
the major hepatic enzyme involved in ramelteon metabolism. 
Four principal metabolites of ramelteon have been identified, 
M-I to M-IV [56]. Among these, M-II has been found to 
occur in a much higher concentrations with systemic levels 
20-100 folds greater than ramelteon itself. Although the 
activity of M-II is 30-fold lower than that of ramelteon, its 
exposure exceeds that of ramelteon by a factor of 30. Hence 
it is suggested that M-II may contribute significantly to the 
net clinical effect of ramelteon. 
 
 
 
 
 
 
 
Fig. (1). Chemical structures of melatonin and ramelteon. 
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Mechanism of Ramelteon Sedative-Hypnotic Action 
 Although MT1 and MT2 receptors are widely distributed 
in the brain outside of the SCN [57-61], the high density of 
melatonin receptors in the SCN and their relationship to the 
circadian pacemaker function and in particular to sleep-wake 
cycle are highly suggestive of the SCN melatonin receptor 
role in sleep regulation. The selectivity of Ramelteon for 
MT1 and MT2 melatonin receptors indicates that its probable 
sleep related site of action is in the SCN. 
 A “sleep-switch” model to describe the regulation of 
sleep-wakefulness was originally proposed by Saper and his 
colleagues [3, 62]. It consists of “flip-flop” reciprocal 
inhibitions among sleep-associated activities in the 
ventrolateral preoptic nucleus and wakefulness associated 
activities in the locus coeruleus, dorsal raphe and 
tuberomammillary nuclei. The SCN has an active role both 
in promoting wakefulness as well as in promoting sleep and 
this depends upon a complex neuronal network and a 
number of neurotransmitters released from networks of 
GABA, glutamate, arginine vasopressin, somatostatin, etc. 
[63, 64]. 
 Ramelteon may accelerate sleep onset by influencing the 
hypothalamic sleep switch downstream from the SCN in the 
same way as that of melatonin [65, 66]. Ramelteon promotes 
sleep onset through inhibition of SCN electrical activity and 
the consequent inhibition of circadian wake signal thereby 
activating the specific sleep-circuit pathway. The 
interrelations of melatonin and SCN in the control of sleep 
are shown in Fig. (2). 
Clinical Studies on Ramelteon 
 The first study on the effects of ramelteon on sleep was 
conducted by Roth and his co-workers in 2005 [67]. In that 
study involving 117 patients (16 to 64 yr) drawn from 13 
centers in Europe, the efficacy, safety and dose response of 
ramelteon were examined. Each patient was randomized to a 
dose sequence of 4, 8, 16 or 32 mg of ramelteon. All doses 
of ramelteon produced a statistically significant reduction in 
latency to persistent sleep (LPS) and increased TST as 
shown by polysomnographic (PSG) [67]. 
 In a follow-up study, the same group of investigators 
administered ramelteon for a period of five weeks to 829 
patients (>65 years) [68]. In this double blind study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). The interrelations  between  melatonin, suprachiasmatic nucleus (SCN) in the control of sleep and circadian rhythms.  Reproduced 
with kind permission of The New England Journal of Medicine; Brzezinski, A.  Melatonin in humans, New Eng J Med, 1997, 336, 186-195. 
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ramelteon, doses of 4 or8 mg/day brought out a significant 
reduction in SOL (16% to 35%). TST was increased by both 
doses of ramelteon. In another randomized, multicenter 
double-blind, placebo-controlled crossover study including 
107 patients followed by PSG, ramelteon was studied in 
doses of 4-32 mg/day [69]. The treatment decreased LPS and 
increased TST significantly. 
 A short term evaluation of the efficacy of ramelteon was 
performed in 100 elderly subjects by administering 4 and 8 
mg doses in a two night/three day period crossover design 
[70]. LPS was decreased, and TST and SE were augmented 
as compared to placebo. Likewise, the efficacy of ramelteon 
in reducing SOL and in increasing TST and SE was 
evaluated in 371 patients given 8 or 16 mg of ramelteon for 5 
weeks in a double-blind, placebo-controlled study [71]. The 
results confirmed the effect of ramelteon to reduce SOL and 
to increase SE and TST [71]. 
 The hypnotic action of ramelteon (8 mg) was so rapid 
that it caused significant reductions in SOL within a week 
(63% for ramelteon vs 39.7% for placebo, p< 0.001) [72]. 
This reduction in LPS was sustained throughout the 5 weeks 
of study (63 and 65.9% ramelteon vs 41.2 and 48.9% 
placebo at the end of the 3
rd
 and 5
th
 week, respectively) [65]. 
Ramelteon (8 mg) reduced LPS and increased TST in 6-
week long study involving healthy women [73]. 
 In another 6 month study performed in 451 adults 
suffering from chronic insomnia drawn from different 
centers across the globe (mainly USA, Europe, Russia and 
Australia), ramelteon consistently reduced LPS when 
compared to placebo [74]. The baseline LPS decreased from 
70.7 to 32.0 minutes at week one (with ramelteon) and this 
reduction in LPS was maintained at months 1, 3, 5 and 6. No 
adverse effects such as next morning residual effects, 
rebound insomnia or withdrawal effects were noted [74]. 
 In a double-blind placebo controlled study involving a 
large number of Japanese patients with chronic insomnia 
(n=1130), the efficacy and safety of 4 and 8 mg ramelteon 
doses were evaluated [75]. No statistically significant 
differences were found in subjective SOL as compared to the 
placebo group with 4 mg/day of ramelteon while with 8 
mg/day of ramelteon a significant increase in TST and a 
decrease in SOL were observed. 
 The same investigators evaluated the efficacy and safety 
of ramelteon in 190 Japanese adults with chronic insomnia 
treated for a period of 24 weeks [76]. TST significantly 
increased with ramelteon (8 mg/day) and this effect was 
maintained for 20 weeks. In this study, ramelteon was well 
tolerated and it did not cause residual effects, rebound 
insomnia, withdrawal symptoms or dependence even after 24 
weeks of continuous treatment [76]. 
 Therefore, in all clinical studies undertaken so far to 
evaluate the efficacy and safety of ramelteon in various 
doses ranging from 4 to 32 mg/day in patients with chronic 
insomnia, the drug reduced SOL and increased sleep 
duration [65, 77]. Besides acting as a sedative-hypnotic drug, 
ramelteon also exhibited chronobiotic properties. In a study 
conducted on 75 healthy human subjects, the administration 
of ramelteon at doses of 1, 2, 4 and 8 mg for 6 days caused 
significant advancement of dim light melatonin offset [78]. 
 Interestingly, data from a recent randomized, placebo-
controlled study suggested that ramelteon can also be 
beneficial for the treatment of ambulatory bipolar I disorder 
patients with manic symptoms and sleep disturbance [79]. 
Twenty-one outpatients with bipolar I disorder with mild-to-
moderate manic symptoms and sleep disturbance were 
randomized to receive either ramelteon (n=10) or placebo 
(n=11) in an 8-week, double-blind, fixed-dose (8 mg/day) 
study. Ramelteon and placebo had similar rates of reduction 
in ratings of symptoms of insomnia, mania, and global 
severity of illness. However, ramelteon was associated with 
improvement in a global rating of depressive symptoms. It 
was also well tolerated and associated with no serious 
adverse events [79]. 
Ramelteon Effects on Sleep Disturbances of Jet Lag 
 Both objective and subjective studies using either 
actigraphy or polysomnography has shown that poor sleep is 
one of the characteristic features seen during time zone 
transitions. Sleep fragmentation, premature awakening, 
difficulty in initiating sleep constitute the most important 
features of jet-lag associated sleep disturbances [80]. The 
effects of transmeridian travel on various sleep parameters 
such as total sleep time, sleep onset latency and sleep offset 
was evaluated in a study in which academicians travelled 
from Japan to USA and Canada back. Significant decreases 
in total sleep time were noted on the second post-travel day 
in eastward travel [81]. Melatonin at a 5 mg dose was 
administered in a double-blind, randomized placebo-
controlled study to evaluate its efficacy on sleep parameters 
where it was found that it increased slow sleep but its effects 
on sleep parameters did not differ much from that of placebo 
[82]. 
 Recently the effects of ramelteon on sleep parameters 
were evaluated in a group of 110 healthy adults with a 
history of jet lag sleep disturbances who were flown from 
Hawaii to the east coast of USA (crossing five time zones). 
Ramelteon was administered in 1, 4 and 8 mg (or placebo), 5 
minutes before local bedtime for four nights. Measurements 
of sleep parameters by using polysomnography revealed that 
ramelteon (1 mg) reduced the mean latency to persistent 
sleep (LPS) on nights 2-4 (P=0.030) compared to placebo 
with no evidence of adverse reports [83]. A Table depicting 
the efficacy of ramelteon in chronic insomnia is presented in 
Table 1. 
Tasimelteon 
 Tasimelteon, (1R-trans)-N-[2-(2, 3dihydro-4benzofuranyl) 
cyclopropyl) methyl]propanamide is also an MT1/MT2 
receptor agonist. In human studies undertaken on 39 healthy 
subjects, this drug decreased the sleep latency, increased 
sleep efficiency and also shifted melatonin rhythm, various 
doses ranging from 10 mg, 20 mg, 50 mg and 100mg were 
used in this study [84]. However the effectiveness and safety 
of tasimelteon in insomnia can be ascertained only after 
undertaking long term studies [85]. 
6-Chloromelatonin (LY156735) 
 Beta-methyl 6-chloromelatonin is another MT1/MT2 
receptor agonist. LY156735 has been shown to induce sleep 
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at all doses tested (20, 35, 50 and 100 mg/day) in placebo 
controlled studies undertaken in healthy volunteers [86]. In a 
double-blind study on 40 patients with chronic insomnia, 6-
chloromelatonin (20, 40 and 100 mg) caused significant 
improvements both in subjective and objective measures of 
sleep onset latency at higher doses but caused a trend of 
improvement at the 20 mg dose [87]. 
Sleep and Circadian rhythm Disturbances, Depression 
and the Use of Agomelatine 
 Depressive patients experience difficulty in falling 
asleep, staying asleep and display early morning wakefulness 
[88]. Disruptions in sleep homeostasis constitute one of the  
major features of depressive illness. Decreased REM sleep 
latency with alteration of temporal distribution of sleep is 
often seen in patients with major depressive disorder [89]. 
Chronic insomnia is considered both as a prominent feature 
as well as predictor of depressive illness [90]. Understanding 
the physiological mechanisms of sleep regulation especially 
their sequellae and their breakdown can help one to unravel 
the complexities of the pathophysiology of depressive 
disorders [90]. Sleep disturbances and changes in sleep form 
three diagnostic criteria for mood disorders in the Diagnostic 
and Statistical Manual of Mental Disorders–Fourth Edition 
(DSM-IV-2000). Profound disturbances in sleep architecture 
have been reported in about 80% of depressive patients with 
major depressive disorders (MDD) or bipolar disorder (BPD) 
[91]. Insomnia often precedes the appearance of mood 
changes [92]. In addition to sleep disturbances disruptions in 
biological rhythms are also strongly associated with mood 
disorders [93, 94]. Mood disorders such as MDD and BPD 
have been shown to be prevalent in individuals that have 
abnormal biological clocks or arrhythmic clocks [95, 96]. In 
addition to this, individuals with genetic sleep disorders also 
manifest symptoms of depression and anxiety [97, 98], 
These include persons with familial advanced phase sleep 
syndrome (FASPS), whose circadian rhythms are shifted 
earlier and, as a result, fall asleep and wake up much earlier 
than desired, or delayed sleep phase syndrome (DSPS) in 
which individuals sleep and wake up later.. Circadian 
rhythms as well as sleep-wake rhythms are regulated by a 
molecular clock located in the SCN of the hypothalamus that 
consists of a transcriptional feedback loop that cycles over 
the course of approximately 24 hr [99, 100]. Abnormalities 
in the functioning of the molecular clock underlie the 
development of mood disorders like MDD and BPD and 
sleep-wake disorders [101]. Although the central circadian 
pacemaker is located in the SCN, the circadian genes that 
make up the molecular clock control the circadian rhythms 
and regulate mood and sleep-wake cycles in normal 
individuals. Genetic variations in the circadian genes have 
been found to associate with sleep disorders and diurnal 
preference measures include an association between certain 
variants of Per 2 and CK1? with FASPS; Per3, CLOCK and 
CK1? with DSPS; and Per1, Per2, and Per3, with diurnal 
preference [102-105]. Analysis of function of these circadian 
genes suggests a connection between mood regulation and 
Table 1. Summary of the Clinical Effects of Ramelteon in Patients with Chronic Insomnia 
 
Number of Patients & 
Nature of Illness 
Dosage 
mg/day 
Duration of 
Administration 
Sleep Onset Latency (SOL) 
Latency to Persistent Sleep (LPS) 
Sleep Efficacy 
& Quality 
Total Sleep time Ref. 
829 
(mean age: 72.4 yrs) 
4 and 8 5 weeks Reduced SOL Enhanced 
Increased at the end of 
1st, 3rd and 5th week 
[68] 
107 
(mean age: 37.7 yrs) 
4, 8, 16 
and 32 
2 days Reducted LPS Increased Increased  [69] 
100 elderly patients 4 and 8 9 weeks Reduced LPS Increased Increased [70] 
371 patients with 
chronic insomnia 
8 and 16 5 weeks Reduced SOL Increased Increased at all doses [71] 
270 patients with 
chronic insomnia 
8 5 weeks 
63% reduced SOL in week 1, 63% 
&65.9% reduced LPS in week 3 & 
5, respectively 
- - [72] 
20 healthy peri- and 
post-menopausal 
women 
8 6 weeks Reduced LPS Increased  Increased  [73] 
451 adults with chronic 
insomnia 
8 6 months Reduced LPS consistently - - [74] 
566 adult patients 
(18-83 years) 
Mean age: 46.7 yrs 
8 2 nights Reduced LPS - - [117]  
289 patients with 
chronic insomnia (65 
yrs) 
8 and 16 5 weeks Reduced LPS Increased 
 
Increased 
 
[118]  
1130 adults 4 and 8  Reduced SOL with 8 mg only 
Increased in the 
first week 
Increased [75] 
190 adults with chronic 
insomnia 
4, 8 and16 24 weeks - Increased 
Increased up to 20 
weeks and then 
maintained 
[76] 
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normal functioning of the circadian clock [106]. Therapeutic 
modalities that shift, reset and stabilize the circadian rhythms 
constitute successful methods of treating sleep-wake and 
mood disorders. While prescribing antidepressants caution 
should be exercised. An ideal antidepressant should not only 
mitigate symptoms of depression, but also should improve 
the sleep quality and efficiency. Although selective serotonin 
reuptake inhibitors (SSRIs) constitute the major class of 
antidepressants that are prescribed, their use in depression 
exacerbates the insomnia of depressive illness [107]. 
 Agomelatine, a melatonergic agonist developed by Servier 
Laboratories (France) is a naphthalenic compound chemically 
designated as [N-[2-(7-methoxynaphthth-1-yl)ethyl] 
acetamide]. It has high affinity for both MT1 and MT2 
melatonergic receptors and also functions as a 5-HT2c receptor 
antagonist. Agomelatine does not exhibit any significant affinity 
towards muscarinic, histaminergic, adrenergic, GABAergic or 
dopaminergic receptors and their subtypes [108, 109]. 
Agomelatine was recently licensed in Europe by the European 
Medicine agencies for treatment of major depressive disorders. 
The efficacy and safety of agomelatine has been has been 
proved in a number of multicenter studies conducted in Europe. 
The noteworthy point emerging from these clinical studies is 
that agomelatine has been clinically effective in doses of 25 -
50mg/day even in a severely depressed population. The clinical 
efficacy of agomelatine in MDD and other mood disorders has 
been reviewed elsewhere [110, 111]. Unlike other 
antidepressants that are in clinical use, agomelatine was 
effective in improving the sleep quality and efficacy of patients 
with MDD, BPD and seasonal affective disorder (SAD). In a 
study conducted on 165 patients of major depressive disorders, 
it was found that agomelatine (25 mg/day) caused earlier and 
improvements on the criteria of “getting into sleep” and quality 
of sleep. These improvements in sleep parameters were evident 
from first week of treatment onwards and this was not the case 
in patients treated with the antidepressant venlafaxine [112]. In 
another study conducted on patients with MDD, agomelatine 
treatment (25 mg/day) for 6 weeks, increased the duration of 
slow wave sleep (SWS) without affecting REM sleep duration. 
In this study, improvements in sleep quality also started from 
the first week of treatment [113, 114]. In a study conducted on 
the effect of agomelatine on cyclic alternating pattern of sleep 
(CAPS), agomelatine (25 mg/day) significantly decreased 
CAPS time and CAPS cycles and normalized NREM sleep in 
depressive patients. The changes in NREM sleep variables 
preceded the improvements in subjective mood suggesting 
thereby that agomelatine’s antidepressant mechanism of action 
is also attributed through its ability in improving the sleep 
quality [115]. Antidepressants that are in clinical use today 
elevate daytime mood by activating central nervous system 
effects. If these energizing effects are sustained into the night it 
will result in impairment of sleep quality [116]. Agomelatine 
has a dual mechanism of actions, of improving sleep quality as 
well as exerting rapid antidepressant actions. Agomelatine’s 
melatonergic effects of sleep promotion counteract the 
antihypnotic effects caused by the 5-HT2c receptor antagonism. 
CONCLUSION 
 Melatonin exhibits both hypnotic and chronobiotic 
properties and thus has been investigated for inducing sleep 
and treating sleep disorders in children, adults, and elderly 
people. The results of clinical studies with melatonin on 
sleep outcomes, however, have not been consistent, probably 
due to its short-half life and and rapid metabolismed after 
oral administration of fast release preparations. 
 The melatonergic agonist, ramelteon (Rozerem
®
) has 
been effective in treating insomnia and sleep-wake rhythm 
disorders. It has shown promising results in the treatment 
and management of insomnia. In a number of clinical trials, 
ramelteon has proved its efficacy as a safe hypnotic drug. 
This melatonergic drug, acting through MT1 and MT2 
melatonergic receptors in brain, particularly the SCN, is 
effective and promising for promoting sleep quality and 
efficiency without adverse side effects compared to 
benzodiazepine and non-benzodiazepine sedative drugs. 
Other melatonergic drugs like tasimelteon or 6-
chloromelatonin also increased sleep efficiency and 
decreased sleep latency. However a larger number of clinical 
trials is needed to prove the efficacy of these molecules for 
the treatment of insomnia. 
 Melatonin-like compounds exert sleep-promoting effects 
by amplifying day/night differences in alertness and sleep 
quality and by displaying effective sleep inducing effects, 
when compared to the efficacy of benzodiazepine or non-
benzodiazepine hypnotic drugs. Because they act in a natural 
way in promoting sleep and their long-term use has not been 
associated with side effects such as dependency, next-day 
hangover, memory impairment, cognitive dysfunction, or 
psychomotor retardation, melatonergic hypnotic drugs, 
especially ramelteon have a promising role in the treatment 
of insomnia. The novel melatonergic antidepressant, 
agomelatine has been shown to produce relatively rapid 
remission of depressive symptoms in a number of clinical 
trials involving a large number of patients selected from 
many European countries. Unlike the other antidepressants 
that are in use, agomelatine exhibits a dual mechanism of 
action of improving both the sleep quality and causing 
remission of depressive symptoms. Unlike the other 
antidepressants that are in clinical use, agomelatine improves 
both night time sleep and day time alertness and thus exerts a 
novel antidepressant effect. 
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